NEW YORK (GenomeWeb News) – UBS today said it has downgraded Bruker BioSciences’ stock to “Neutral" from "Buy."

 

According to Reuters, the brokerage said Bruker’s Daltonics division “faces increasing competition from much larger mass spectrometry vendors, potentially limiting upside.”

 

UBS maintained its $7 price target on Bruker’s stock, Reuters said.

 

The stock was down 1.62 percent, or $.10, at 6.04 in mid-afternoon trading today.